



Effects of rapamycin against paraquat-induced pulmonary fibrosis in mice^{*}

Xue SHAO, Meng LI, Chong LUO, Ying-ying WANG, Ying-ying LU, Shi FENG, Heng LI, Xia-bing LANG, Yu-cheng WANG, Chuan LIN, Xiu-jin SHEN, Qin ZHOU, Hong JIANG, Jiang-hua CHEN^{†‡}

(Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China)

[†]E-mail: chenjianghua@zju.edu.cn

Received Aug. 18, 2014; Revision accepted Oct. 9, 2014; Crosschecked Dec. 24, 2014

Abstract: Background and aims: Ingestion of paraquat (PQ), a widely used herbicide, can cause severe toxicity in humans, leading to a poor survival rate and prognosis. One of the main causes of death by PQ is PQ-induced pulmonary fibrosis, for which there are no effective therapies. The aim of this study was to evaluate the effects of rapamycin (RAPA) on inhibiting PQ-induced pulmonary fibrosis in mice and to explore its possible mechanisms. Methods: Male C57BL/6J mice were exposed to either saline (control group) or PQ (10 mg/kg body weight, intraperitoneally; test group). The test group was divided into four subgroups: a PQ group (PQ-exposed, non-treated), a PQ+RAPA group (PQ-exposed, treated with RAPA at 1 mg/kg intragastrically), a PQ+MP group (PQ-exposed, treated with methylprednisolone (MP) at 30 mg/kg intraperitoneally), and a PQ+MP+RAPA group (PQ-exposed, treated with MP at 30 mg/kg intraperitoneally and with RAPA at 1 mg/kg intragastrically). The survival rate and body weight of all the mice were recorded every day. Three mice in each group were sacrificed at 14 d and the rest at 28 d after intoxication. Lung tissues were excised and stained with hematoxylin-eosin (H&E) and Masson's trichrome stain for histopathological analysis. The hydroxyproline (HYP) content in lung tissues was detected using an enzyme-linked immunosorbent assay (ELISA) kit. The expression of transforming growth factor- β 1 (TGF- β 1) and α -smooth muscle actin (α -SMA) in lung tissues was detected by immunohistochemical staining and Western blotting. Results: A mice model of PQ-induced pulmonary fibrosis was established. Histological examination of lung tissues showed that RAPA treatment moderated the pathological changes of pulmonary fibrosis, including alveolar collapse and interstitial collagen deposition. HYP content in lung tissues increased soon after PQ intoxication but had decreased significantly by the 28th day after RAPA treatment. Immunohistochemical staining and Western blotting showed that RAPA treatment significantly down-regulated the enhanced levels of TGF- β 1 and α -SMA in lung tissues caused by PQ exposure. However, RAPA treatment alone could not significantly ameliorate the lower survival rate and weight loss of treated mice. MP treatment enhanced the survival rate, but had no significant effects on attenuating PQ-induced pulmonary fibrosis or reducing the expression of TGF- β 1 and α -SMA. Conclusions: This study demonstrates that RAPA treatment effectively suppresses PQ-induced alveolar collapse and collagen deposition in lung tissues through reducing the expression of TGF- β 1 and α -SMA. Thus, RAPA has potential value in the treatment of PQ-induced pulmonary fibrosis.

Key words: Paraquat, Pulmonary fibrosis, Rapamycin, Transforming growth factor- β 1, α -Smooth muscle actin, Methylprednisolone

doi:10.1631/jzus.B1400229

Document code: A

CLC number: R563.9

[‡] Corresponding author

^{*} Project supported by the National Key Technology R&D Program of China (No. 2011BA110B07), the National Basic Research Program (973) of China (No. 2012CB517603), and the National High-Tech R&D Program (863) of China (No. 2012AA02A512)

ORCID: Jiang-hua CHEN, <http://orcid.org/0000-0002-3282-3998>

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2015

1 Introduction

Paraquat (*N,N*-dimethyl-4,4'-bipyridinium dichloride; PQ) is one of the most widely used herbicides in developing countries. However, it is also a highly toxic compound for both humans and animals,

which accounts for a high mortality rate each year resulting from accidental or voluntary ingestion (Vale *et al.*, 1987; Baltazar *et al.*, 2013). Regular care of PQ-poisoned patients, including gastric lavage and haemoperfusion, does not reduce their mortality rate. This is mainly because PQ selectively accumulates in the lungs, leading to irreversible pulmonary fibrosis. Previous studies have revealed that a combination of glucocorticoid and cyclophosphamide can improve the survival rate of PQ-poisoned patients or animal models, and reduce the pathological changes in the lung tissues, such as inflammatory cell infiltration, in the early stages of acute lung injury (ALI) (Rocco *et al.*, 2003; Li *et al.*, 2014), but this therapy does not have a significant effect in preventing progressive pulmonary fibrosis. Some other potential agents, such as docosahexaenoic acid (DHA) (Chen J. *et al.*, 2013) and naringin (Chen Y. *et al.*, 2013; Blanco-Ayala *et al.*, 2014), have been shown to ameliorate PQ-induced pulmonary fibrosis in animal models. However, these new therapies take a relatively long time to achieve a noticeable antifibrotic effect. Therefore, more effective therapies are urgently required.

Rapamycin (RAPA), also known as sirolimus, is a potent inhibitor of the mammalian target of rapamycin (mTOR), which has been increasingly used to prevent graft rejection in solid organ transplantation because of its immunosuppressive effects. RAPA is also attractive in clinical practice due to its potent antifibrotic property. The mTOR protein is a serine-threonine kinase known to be central to a complex intracellular signaling pathway and involved in the processes of cell growth and proliferation. Downstream of mTOR are two main effectors, p70S6 kinase and the translation inhibitor 4E binding protein 1, both of which control the translation of specific mRNAs and the synthesis of particular proteins. RAPA binds intracellularly to the FK506 (tacrolimus)-binding protein to form a complex, which subsequently binds to mTOR to inhibit its ability to signal adequately to its downstream effectors (Hartford and Ratain, 2007). It has been reported that in animal models RAPA can attenuate progressive chronic kidney diseases, such as tubulointerstitial fibrosis, diabetic nephropathy and compensatory renal hypertrophy (Bonogio *et al.*, 2005; Chen J.K. *et al.*, 2005; Lloberas *et al.*, 2006). In rat models of liver fibrosis, low-dose RAPA treatment can reduce collagen deposition (Neef *et al.*, 2006). More recently, several studies have revealed that

RAPA can prevent the progression of bleomycin- or transforming growth factor- α (TGF- α)-induced pulmonary fibrosis (Korfhagen *et al.*, 2009; Madala *et al.*, 2011). As a result, we hypothesized that RAPA treatment may be an effective therapy to ameliorate PQ-induced pulmonary fibrosis.

Pulmonary fibrosis is characterized by fibroblast proliferation, myofibroblast differentiation, and deposition of extra-cellular matrix (ECM) in the lung parenchyma (Tulek *et al.*, 2011). TGF- β 1 is a key fibrogenic cytokine, which plays a critical role in the expression of α -smooth muscle actin (α -SMA) and induction of lung fibrosis (Oka *et al.*, 2013). α -SMA is the hallmark of myofibroblasts, which are generally considered to be the key effector cells in the development of fibrosis (Wang *et al.*, 2012). The aim of this study was to evaluate RAPA treatment as a potential novel therapy for attenuating PQ-induced pulmonary fibrosis by assessing its effects on the survival rate, body weight, histology, and hydroxyproline (HYP) content of PQ-treated mice. The possible mechanisms of RAPA treatment in this model were also studied.

2 Materials and methods

2.1 Animals

This study was performed on healthy male C57BL/6J mice, 6 to 8 weeks old, weighing between 20 and 22 g, and kept in the animal center of Zhejiang University, China. The animals were housed in a ventilated room at (22 \pm 2) °C with a 12-h dark/12-h light cycle and provided with free access to fresh water and standard rodent chow.

2.2 Experimental design

The mice were assigned to either a control group or test groups, each group containing six mice. All the animals were weighed before treatment and then daily throughout the experiment.

In the control group, saline (10 ml/kg body weight) was administered intraperitoneally and then dimethyl sulfoxide (DMSO; 10 ml/kg body weight) was given intragastrically daily. Mice in the test groups received PQ (dissolved in saline) at 10 mg/kg body weight intraperitoneally on Day 0. The mice in the test groups were divided according to the treatment received during the experiment as follows:

(1) PQ group: mice in this group were treated daily with DMSO intragastrically 1 h after PQ administration; (2) PQ+RAPA group: mice in this group were treated daily with RAPA (1 mg/kg, intragastrically) dissolved in DMSO 1 h after PQ administration; (3) PQ+MP group: mice in this group were treated with a single dose injection of MP (30 mg/kg, intraperitoneally) 1 h after PQ administration and then daily with DMSO intragastrically; (4) PQ+MP+RAPA group: mice in this group were treated with a single dose injection of MP (30 mg/kg, intraperitoneally) 1 h after PQ administration and then daily with RAPA (1 mg/kg, intragastrically). Three mice in each group were sacrificed at 14 d and the rest at 28 d after PQ exposure.

2.3 Lung preparation

The animals were anesthetized with pentobarbital sodium (10 mg/kg body weight, intraperitoneally) and killed by exsanguination via the arteria angularis. After perfusion of the lungs with 10 ml of normal saline via the right ventricle, individual lung lobes were removed en bloc for further experimentation.

2.4 Morphological analysis

The left lower lung lobes were inflation-fixed overnight with 10% neutral buffered formalin. After fixation, lung tissues were embedded in paraffin and cut into 2- μ m sections on a cryostat-microtome (Leica Microsystems Nussloch GmbH, RM2245). To visualize the overall tissue architecture and collagen deposition, representative sections were stained with hematoxylin-eosin (H&E) and Masson's trichrome stain. Stained sections were viewed using a microscope (Leica Microsystems Wetzlar GmbH, DFC490) at a magnification of 400 \times , and the images were analyzed using LAS AF Lite V3.6 software.

2.5 HYP content assay

Lung tissues (30 mg) from each mouse were rinsed with 1 \times phosphate buffer saline (PBS), and then homogenized in 0.3 ml radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors (Beyotime Institute of Biotechnology, st506-1) at 4 °C. The homogenate was centrifuged for 45 min at 15000 r/min at 4 °C. The supernatant was collected immediately. The HYP content of the supernatant was then determined using an

HYP enzyme-linked immunosorbent assay (ELISA) kit (MyBioSource, MBS703512) according to the manufacturer's instructions.

2.6 Immunohistochemical staining of lung sections

Paraffin sections with 2- μ m thickness were dewaxed in xylene and rehydrated in grade alcohol, and then subjected to heat-mediated antigen retrieval in a pressure cooker. To block endogenous peroxidase activity, sections were immersed in 0.3% H₂O₂ for 30 min, followed by a serum block with 5% non-fat dry milk for 30 min. The sections were then incubated with primary monoclonal mouse anti-TGF- β 1 antibody (1:40 (v/v), R&D, MAB240) at 4 °C overnight and anti- α -SMA antibody (1:100 (v/v), Abcam, ab7817) at 37 °C for 1 h. After washing three times with PBS (pH 7.4) for 5 min each, the sections were incubated with horseradish peroxidase (HRP)-conjugated secondary anti-mouse antibody (Gene Tech, GK500705) for 30 min at room temperature and then developed by diaminobenzidine (DAB). The sections were restained with hematoxylin for 1 min and then dehydrated, cleared, and mounted. Stained sections were photographed using a Leica microscope (Leica Microsystems Wetzlar GmbH, DFC490), and the images were analyzed using LAS AF Lite V3.6 software.

2.7 Western blots

Lung tissues were minced and homogenized in 1 ml radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors (Beyotime Institute of Biotechnology, st506-1) at 4 °C. Supernatants were collected after 45 min of centrifugation at 15000 r/min. Protein concentrations were measured by BCA protein assay (Thermo Scientific, MK166714). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate denatured proteins (100 °C, 5 min; 30 μ g per lane). Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Bio-Rad, 162-0177) by electroblotting (Bio-Rad, Power Pac Basic). Blots were blocked at room temperature for 2 h with Tris-buffered saline and Tween 20 (TBST) containing 5% (0.05 g/ml) fat-free milk powder, and were subsequently incubated overnight at 4 °C with primary monoclonal mouse anti- α -SMA antibody (1:500 (v/v), Abcam, ab7817) and anti-TGF- β 1 antibody (1:1000 (v/v), R&D, MAB240). Monoclonal mouse anti- β -actin

antibody at 1:2000 (v/v) dilution (Dawen Biotech, DW9562) was also added as an internal control. Blots were washed three times with TBST for 10 min each and then incubated for 30 min at room temperature with HRP-conjugated secondary anti-mouse antibodies (1:2000 (v/v), Abbkine, A21010-1). After rinsing, signals were detected using electrochemiluminescence (ECL; Biological Industries, 1236507) and scanned with a ChemiDoc MP System (Bio-Rad). The intensity of protein bands was analyzed using Image Lab 4.1 software (Bio-Rad).

2.8 Statistical analysis

Data are presented as mean±standard deviation (SD). All analyses were performed using GraphPad Prism 5.0 software (GraphPad Inc., San Diego, CA, USA). Statistical comparisons were performed using one-way analysis of variance (ANOVA). The significance of survival curves was estimated by the Kaplan-Meier method with a log-rank test. *P* value of <0.05 was considered statistically significant for all experiments.

3 Results

3.1 Survival rate of mice

At 7 d after PQ intoxication, MP treatment had significantly increased the survival rate, with 95% survival in the PQ+MP group ($P<0.05$) and 96% in the PQ+MP+RAPA group ($P<0.05$) compared with 70% in the PQ group. RAPA treatment improved the survival rate to 82% in the PQ+RAPA group compared with 70% in the PQ group, and to 96% in the PQ+MP+RAPA group compared with 95% in the PQ+MP group, but the improvements were not statistically significant (Fig. 1).

3.2 Body weight changes

There was a remarkable loss of weight 1 d after PQ intoxication (PQ group, PQ+MP group vs. control, $P<0.05$; PQ+RAPA group, PQ+MP+RAPA group vs. control, $P<0.001$; Fig. 2). Instead of attenuating the body weight loss, RAPA treatment was also associated with weight loss, but the reduction was not statistically significant. By the 7th day after PQ administration, the body weight of mice in all the test groups had recovered to baseline.




Fig. 1 Survival rate analysis

MP treatment significantly increased the survival rate ($n=6$; $*P<0.05$, compared with PQ group). The survival rate was recorded up to 7 d after RAPA or DMSO treatment. The survival rates were estimated by the Kaplan-Meier method and compared by a log-rank test




Fig. 2 Body weight changes

PQ intoxication caused a marked weight loss after one day ($*P<0.05$, $***P<0.001$, compared with control). There was also a body weight reduction after RAPA treatment, but it was not statistically significant

3.3 Morphopathological changes in lung tissues

Typical morphopathological changes in the lung tissues from the mice 14 and 28 d after pulmonary fibrosis induction are shown in Fig. 3. Compared with the lung tissues of the mice in the PQ and PQ+MP groups, those of the PQ+RAPA and PQ+MP+RAPA groups presented with significantly less pulmonary fibrosis. Gross examination of lungs from the PQ and PQ+MP groups 14 d after intoxication revealed dark red coloration with evident hemorrhagic foci on the surface, whereas lungs from RAPA-treated mice appeared nearly normal compared with those of mice in the control group (Fig. 3a). H&E staining revealed diffuse alveolar collapse and thickening in lung tissue sections of the PQ and PQ+MP groups. These changes were ameliorated by RAPA treatment. Masson's trichrome staining also showed diffuse perialveolar, peribronchial, and interstitial fibrosis in lung tissue sections of the PQ and PQ+MP groups. In lung tissue

sections of the PQ+RAPA and PQ+MP+RAPA groups, however, there was mild collagen deposition. Effects of MP treatment (PQ+MP and PQ+MP+RAPA groups) against pulmonary fibrosis were not evident when the MP groups were compared with the PQ group and the PQ+RAPA group (Fig. 3a). The PQ-induced pathological changes in gross appearance, H&E staining, and Masson's trichrome staining in lung tissues were more markedly blocked after RAPA treatment after 28 d (Fig. 3b).

3.4 HYP content analysis of lung tissues

Pulmonary fibrosis is characterized by the accumulation of collagen. Because HYP is found uniquely

in collagen (Helene *et al.*, 1999), HYP content was determined to assess further the severity of the fibrosis presented in lung tissues (Fig. 4).

HYP content in lung tissues of the mice in the PQ group was significantly increased ($P<0.05$, compared with control). HYP content decreased after RAPA treatment for 14 d, but not significantly. HYP content also decreased significantly in the lung tissues of the mice in the PQ+RAPA and PQ+MP+RAPA groups, compared with the PQ and PQ+MP groups, respectively, 28 d after RAPA treatment (both $P<0.05$), indicating that PQ-induced increased collagen deposition was attenuated. MP treatment did not significantly reduce the HYP content.




Fig. 3 Morphopathological changes in lung tissues

Mice were treated with a single dose injection of MP 1 h after PQ administration and then DMSO or RAPA once daily for 14 d (a) or 28 d (b). The gross appearance, H&E staining, and Masson's trichrome staining of lung tissue sections showed less focal hemorrhage, alveolar collapse and thickening, and interstitial collagen deposition, indicating that RAPA treatment could prevent PQ-induced pulmonary fibrosis. The PQ-induced pathological changes after 28 d (b) were more markedly blocked by RAPA treatment than those after 14 d (a). However, no effect of MP treatment against pulmonary fibrosis was observed




Fig. 4 Changes of hydroxyproline (HYP) content in lung tissues

(a) HYP content decreased after RAPA treatment for 14 d compared with that of non-treated PQ-poisoned mice, but the decrease was not statistically significant. (b) HYP content had decreased significantly in lung tissues of the mice in the PQ+RAPA and PQ+MP+RAPA groups, compared with the PQ and PQ+MP groups, respectively, 28 d after RAPA treatment. Data are expressed as mean±SEM (*n*=6). * *P*<0.05, compared with control; # *P*<0.05, compared with PQ group; † *P*<0.05, compared with PQ+MP group

3.5 Expression of TGF-β1 and α-SMA in lung tissues

The expression of TGF-β1 and α-SMA in lung tissues 14 and 28 d after PQ intoxication is summarized in Figs. 5 and 6.

Low levels of TGF-β1 and α-SMA were detected in lung tissues of the mice in the control group. However, there was increased deposition of TGF-β1 and α-SMA 14 d after poisoning in the PQ group and the PQ+MP group (Fig. 5a). The immunohistochemical staining of α-SMA and TGF-β1 was reduced in lung tissues from the mice treated with RAPA. MP treatment had no significant effects on the regulation of the expression of α-SMA and TGF-β1. The intense staining of TGF-β1 and α-SMA in lung tissues of PQ-poisoned mice was more significantly blocked after RAPA treatment for 28 d (Fig. 5b).

PQ exposure for 14 d (Figs. 6a–6c) and 28 d (Figs. 6d–6f) resulted in a significant increase in the expression of protein levels of TGF-β1 (PQ group, PQ+MP group vs. control: *P*<0.05 or *P*<0.001; Figs. 6b and 6e) and α-SMA (PQ group vs. control: *P*<0.001; PQ+MP group vs. control: *P*<0.01 or *P*<0.001; Figs. 6c and 6f) in lung tissues from the mice of the PQ and PQ+MP groups. In addition, the protein levels of TGF-β1 (PQ+RAPA group vs. PQ group: *P*<0.05 or *P*<0.01; PQ+MP+RAPA group vs. PQ+MP group: *P*<0.01; Figs. 6b and 6e) and α-SMA (PQ+RAPA group




Fig. 5 Immunohistochemical staining of TGF-β1 and α-SMA in lung tissues

The stainings of TGF-β1 and α-SMA (brown in the cytoplasm) were markedly down-regulated by RAPA treatment for 14 d (a) and 28 d (b) after PQ intoxication (Note: for interpretation of the references to color in this figure legend, the reader is referred to the web version of this article)




Fig. 6 Protein levels of TGF-β1 and α-SMA in lung tissues

The protein levels of TGF-β1 and α-SMA were significantly reduced by RAPA treatment for 14 d (a–c) and 28 d (d–f), respectively. Data are expressed as mean±SEM ($n=6$). * $P<0.05$, ** $P<0.01$, *** $P<0.001$, compared with control; # $P<0.05$, ## $P<0.01$, ### $P<0.001$, compared with PQ group; †† $P<0.01$, ††† $P<0.001$, compared with PQ+MP group. The blots with anti-TGF-β1 antibody and anti-α-SMA antibody are shown in (a) and (d), respectively, and densitometric analysis normalized against β-actin is shown in (b), (c), (e), and (f)

vs. PQ group: $P<0.01$ or $P<0.001$; PQ+MP+RAPA group vs. PQ+MP group: $P<0.01$ or $P<0.001$; Figs. 6c and 6f) were markedly down-regulated by RAPA treatment for 14 and 28 d, respectively. MP treatment had no significant effects on regulating the protein levels of TGF-β1 and α-SMA.

4 Discussion

The purpose of this study was to examine the antifibrotic effects of RAPA, an increasingly used immunosuppressant, in a mice model of PQ-induced pulmonary fibrosis. Our results showed that RAPA

treatment could attenuate pulmonary fibrosis progression (Figs. 3 and 4) through down-regulating the expression of TGF-β1 and α-SMA (Figs. 5 and 6). However, RAPA did not significantly improve the survival rate or reduce the loss of body weight in this model (Figs. 1 and 2).

The significant attenuation of alveolar collapse and collagen deposition in histological changes after RAPA treatment was comparable to the effects obtained previously with this model using other potential antifibrotic agents such as DHA and naringin (Chen J. et al., 2013; Chen Y. et al., 2013; Blanco-Ayala et al., 2014). Interestingly, the observation period of the test groups in our study (14 and 28 d after RAPA treatment)

differed from that of other studies of novel antifibrotic agents mentioned above. Our results showed that the therapy of RAPA treatment for 14 d could ameliorate progressive pulmonary fibrosis, and the antifibrotic effects were more obvious in the lung tissues of the mice given RAPA for 28 d. The more rapid effect of RAPA compared with DHA (35 d) and naringin (21 d) suggests that RAPA treatment may have a more potent anti-fibrogenesis impact. The key effector cells in the development of pulmonary fibrosis are myofibroblasts (Wang *et al.*, 2012), which are thought to arise from proliferation or differentiation of resident lung fibroblasts, epithelial-to-mesenchymal transition (EMT) and recruitment of circulating fibrocytes (Tulek *et al.*, 2011; Kendall and Feghali-Bostwick, 2014). Various cytokines, growth factors, and signaling pathways are involved in these events. TGF- β 1 is one of the most potent fibrogenic cytokines to drive EMT, fibroblast proliferation, and myofibroblast differentiation, and then induce ECM production (Cui *et al.*, 2011; Chen *et al.*, 2014). Previous studies have demonstrated that TGF- β 1 contributes to the progress of PQ-induced lung fibrosis (Chen C.M. *et al.*, 2005; Cutroneo *et al.*, 2007). Moreover, inhibition of TGF- β 1 activity or its signaling pathways can significantly attenuate PQ-induced pulmonary fibrosis (Chen Y. *et al.*, 2013). On the other hand, the mTOR protein is involved in the growth and proliferation of fibrosis response cells (Hartford and Ratain, 2007; Xu *et al.*, 2013). As an inhibitor of mTOR, RAPA is thought to affect the cell cycle through the FK506-RAPA complex, by increasing p27 levels in S phase and decreasing p21 levels in G₁ phase, to diminish the number of interstitial fibroblasts and myofibroblasts (Biecker *et al.*, 2005). Recent research also suggests that TGF- β signals via not only Smad-2 and Smad-3, but also the AKT/mTOR axis (Geissler and Schlitt, 2010). In the present study, RAPA treatment displayed inhibitory effects on the expression of TGF- β 1 and α -SMA along with a reduction in HYP content. These results provide further evidence for the antifibrotic effects of RAPA treatment and support the potential role of TGF- β 1 in PQ-induced pulmonary fibrosis.

Despite the promising antifibrotic effects of RAPA on pulmonary fibrosis shown in our study, the survival rate failed to improve significantly after RAPA treatment alone. However, the mice that

received the combination of RAPA and MP treatments had a longer life expectancy. We suggest two possible reasons for this. RAPA has an insignificant effect on ameliorating the progression of ALI, which accounts for early mortality after PQ intoxication (Park *et al.*, 2014). On the other hand, MP, a kind of synthetic corticosteroid drug, can improve the survival rate of PQ patients mainly because of its potent anti-inflammatory effects (Chen G.H. *et al.*, 2002; Wu *et al.*, 2014). In our study, MP treatment did not alleviate pulmonary fibrosis. This finding is in agreement with the conclusions of some recent studies which indicated that MP treatment could decrease inflammatory cell infiltration, but could not further improve lung histology (Chen C.M. *et al.*, 2002). Our study also showed that RAPA treatment could not block the trend of body weight loss and may even worsen it. This result was inconsistent with some previous studies (Korfhagen *et al.*, 2009; Madala *et al.*, 2011). We speculate that this discrepancy may be caused mainly by the different animal models established: TGF- α - and bleomycin-induced pulmonary fibrosis might have less severe lung damage and a lower incidence of multiple organ dysfunction syndrome (MODS). The reduction in body weight after RAPA treatment indicated that RAPA had adverse effects on the PQ-poisoned mice, caused mainly by its immunosuppressive property (Pham *et al.*, 2004; Lee and Gabardi, 2012).

In summary, our study showed for the first time that RAPA has significant inhibitory effects on progressive pulmonary fibrosis in the PQ intoxication mice model. These effects may be partly ascribed to the inhibition of TGF- β 1. In some clinical practices, this agent has been used to rescue PQ-poisoned patients (Barrueto *et al.*, 2008; Lorenzen *et al.*, 2010), but the success rate is not adequate. Hence, further studies of RAPA are needed to confirm its suitability as a new antifibrotic agent in PQ-induced pulmonary fibrosis.

Compliance with ethics guidelines

Xue SHAO, Meng LI, Chong LUO, Ying-ying WANG, Ying-ying LU, Shi FENG, Heng LI, Xia-bing LANG, Yu-cheng WANG, Chuan LIN, Xiu-jin SHEN, Qin ZHOU, Hong JIANG, and Jiang-hua CHEN declare that they have no conflict of interest.

All institutional and national guidelines for the care and use of laboratory animals were followed.

References

- Baltazar, T., Dinis-Oliveira, R.J., Duarte, J.A., et al., 2013. Paraquat research: do recent advances in limiting its toxicity make its use safer? *Br. J. Pharmacol.*, **168**(1):44-45. [doi:10.1111/j.1476-5381.2012.02017.x]
- Barrueto, F., Lee, C., Pajoumand, M., et al., 2008. Use of sirolimus in a case of severe paraquat poisoning. *Clin. Toxicol.*, **46**(8):778-779. [doi:10.1080/15563650701546219]
- Biecker, E., de Gottardi, A., Neef, M., et al., 2005. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. *J. Pharmacol. Exp. Ther.*, **313**(3):952-961. [doi:10.1124/jpet.104.079616]
- Blanco-Ayala, T., Andérica-Romero, A.C., Pedraza-Chaverri, J., 2014. New insights into antioxidant strategies against paraquat toxicity. *Free Radic. Res.*, **48**(6):623-640. [doi:10.3109/10715762.2014.899694]
- Bonegio, R.G., Fuhro, R., Wang, Z., et al., 2005. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. *J. Am. Soc. Nephrol.*, **16**(7):2063-2072. [doi:10.1681/ASN.2004030180]
- Chen, C.M., Su, B., Hsu, C.C., et al., 2002. Methylprednisolone does not enhance the surfactant effects on oxygenation and histology in paraquat-induced rat lung injury. *Intensive Care Med.*, **28**(8):1138-1144. [doi:10.1007/s00134-002-1350-2]
- Chen, C.M., Chou, H.C., Hsu, H.H., et al., 2005. Transforming growth factor- β 1 upregulation is independent of angiotensin in paraquat-induced lung fibrosis. *Toxicology*, **216**(2-3):181-187. [doi:10.1016/j.tox.2005.08.004]
- Chen, G.H., Lin, J.L., Huang, Y.K., 2002. Combined methylprednisolone and dexamethasone therapy for paraquat poisoning. *Crit. Care Med.*, **30**(11):2584-2587. [doi:10.1097/00003246-200211000-00030]
- Chen, J., Zeng, T., Zhao, X., et al., 2013. Docosahexaenoic acid (DHA) ameliorates paraquat-induced pulmonary fibrosis in rats possibly through up-regulation of Smad 7 and SnoN. *Food Chem. Toxicol.*, **57**:330-337. [doi:10.1016/j.fct.2013.03.045]
- Chen, J.K., Chen, J., Neilson, E.G., et al., 2005. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. *J. Am. Soc. Nephrol.*, **16**(5):1384-1391. [doi:10.1681/ASN.2004100894]
- Chen, T., Nie, H., Gao, X., et al., 2014. Epithelial-mesenchymal transition involved in pulmonary fibrosis induced by multi-walled carbon nanotubes via TGF- β /Smad signaling pathway. *Toxicol. Lett.*, **226**(2):150-162. [doi:10.1016/j.toxlet.2014.02.004]
- Chen, Y., Nie, Y.C., Luo, Y.L., et al., 2013. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice. *Food Chem. Toxicol.*, **58**:133-140. [doi:10.1016/j.fct.2013.04.024]
- Cui, Y., Robertson, J., Maharaj, S., et al., 2011. Oxidative stress contributes to the induction and persistence of TGF- β 1 induced pulmonary fibrosis. *Int. J. Biochem. Cell Biol.*, **43**(8):1122-1133. [doi:10.1016/j.biocel.2011.04.005]
- Cutroneo, K.R., White, S.L., Phan, S.H., et al., 2007. Therapies for bleomycin induced lung fibrosis through regulation of TGF- β 1 induced collagen gene expression. *J. Cell. Physiol.*, **211**(3):585-589. [doi:10.1002/jcp.20972]
- Geissler, E.K., Schlitt, H.J., 2010. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. *Kidney Int.*, **78**(11):1075-1079. [doi:10.1038/ki.2010.324]
- Hartford, C.M., Ratain, M.J., 2007. Rapamycin: something old, something new, sometimes borrowed and now renewed. *Clin. Pharmacol. Ther.*, **82**(4):381-388. [doi:10.1038/sj.clpt.6100317]
- Helene, M., Lake-Bullock, V., Zhu, J., et al., 1999. T cell independence of bleomycin-induced pulmonary fibrosis. *J. Leukoc. Biol.*, **65**(2):187-195.
- Kendall, R.T., Feghali-Bostwick, C.A., 2014. Fibroblasts in fibrosis: novel roles and mediators. *Front. Pharmacol.*, **5**:123. [doi:10.3389/fphar.2014.00123]
- Korfhagen, T.R., Le Cras, T.D., Davidson, C.R., et al., 2009. Rapamycin prevents transforming growth factor- α -induced pulmonary fibrosis. *Am. J. Respir. Cell Mol. Biol.*, **41**(5):562-572. [doi:10.1165/rcmb.2008-0377OC]
- Lee, R.A., Gabardi, S., 2012. Current trends in immunosuppressive therapies for renal transplant recipients. *Am. J. Health Syst. Pharm.*, **69**(22):1961-1975. [doi:10.2146/ajhp.110624]
- Li, L.R., Sydenham, E., Chaudhary, B., et al., 2014. Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis. *Cochrane Database Syst. Rev.*, **8**:CD008084. [doi:10.1002/14651858.CD008084.pub4]
- Lloberas, N., Cruzado, J.M., Franquesa, M., et al., 2006. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. *J. Am. Soc. Nephrol.*, **17**(5):1395-1404. [doi:10.1681/ASN.2005050549]
- Lorenzen, J.M., Schonenberger, E., Hafer, C., et al., 2010. Failed rescue therapy with rapamycin after paraquat intoxication. *Clin. Toxicol.*, **48**(1):84-86. [doi:10.3109/15563650903376089]
- Madala, S.K., Maxfield, M.D., Davidson, C.R., et al., 2011. Rapamycin regulates bleomycin-induced lung damage in SP-C-deficient mice. *Pulm. Med.*, **2011**:653524. [doi:10.1155/2011/653524]
- Neef, M., Ledermann, M., Saegesser, H., et al., 2006. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. *J. Hepatol.*, **45**(6):786-796. [doi:10.1016/j.jhep.2006.07.030]
- Oka, H., Ishii, H., Iwata, A., et al., 2013. Inhibitory effects of pitavastatin on fibrogenic mediator production by human lung fibroblasts. *Life Sci.*, **93**(25-26):968-974. [doi:10.1016/j.lfs.2013.10.026]

- Park, J.S., Park, K.H., Kim, H., et al., 2014. Effects of sivelestat treatment on acute lung injury in paraquat-intoxicated rats. *Drug Chem. Toxicol.*, **37**(1):114-120. [doi:10.3109/01480545.2013.834351]
- Pham, P.T., Pham, P.C., Danovitch, G.M., et al., 2004. Sirolimus-associated pulmonary toxicity. *Transplantation*, **77**(8): 1215-1220. [doi:10.1097/01.TP.0000118413.92211.B6]
- Rocco, P.R., Souza, A.B., Faffe, D.S., et al., 2003. Effect of corticosteroid on lung parenchyma remodeling at an early phase of acute lung injury. *Am. J. Respir. Crit. Care Med.*, **168**(6):677-684. [doi:10.1164/rccm.200302-256OC]
- Tulek, B., Kiyani, E., Toy, H., et al., 2011. Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in rats. *Clin. Invest. Med.*, **34**(6):E341.
- Vale, J.A., Meredith, T.J., Buckley, B.M., 1987. Paraquat poisoning: clinical features and immediate general management. *Hum. Toxicol.*, **6**(1):41-47. [doi:10.1177/096032718700600107]
- Wang, J., Yu, Z.H., Zhou, Z.Y., et al., 2012. Inhibition of α -SMA by the ectodomain of FGFR2c attenuates lung fibrosis. *Mol. Med.*, **18**:992-1002. [doi:10.2119/molmed.2011.00425]
- Wu, W.P., Lai, M.N., Lin, C.H., et al., 2014. Addition of immunosuppressive treatment to hemoperfusion is associated with improved survival after paraquat poisoning: a nationwide study. *PLoS ONE*, **9**(1):e87568. [doi:10.1371/journal.pone.0087568]
- Xu, X., Wan, X., Geng, J., et al., 2013. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. *Exp. Biol. Med.*, **238**(9):1082-1094. [doi:10.1177/1535370213498976]

中文概要

题目: 雷帕霉素对小鼠百草枯中毒导致肺纤维化的治疗作用

目的: 评估雷帕霉素 (RAPA) 对小鼠百草枯 (PQ) 中毒导致肺纤维化的治疗作用, 并初步探讨其作用机制。

创新点: 首次在小鼠 PQ 中毒的模型中证明 RAPA 可明显抑制肺纤维化, 且此作用与转化生长因子- β 1 (TGF- β 1) 的抑制相关。

方法: 将 C57BL/6J 雄鼠分为对照组 (腹腔注射生理盐水) 和实验组 (腹腔注射 10 mg/kg PQ)。实验组根据采用的治疗不同, 可分为以下四组: PQ 组、PQ+RAPA 组、PQ+MP (甲强龙) 组和 PQ+MP+RAPA 组。用苏木精-伊红染色法 (H&E) 和马松 (Masson) 三色染色法观察肺组织病理结构变化, 用酶联免疫吸附测定 (ELISA) 试剂盒检测肺组织中的羟脯氨酸 (HYP) 含量, 用免疫组化和免疫印迹的方法检测 TGF- β 1 和 α -平滑肌肌动蛋白 (α -SMA) 的表达水平。

结论: 本实验中小鼠的肺组织病理染色结果显示, RAPA 治疗能缓解肺纤维化导致的病理改变 (图 3)。ELISA 实验结果显示, RAPA 治疗 28 天后可显著降低肺组织中 HYP 的含量 (图 4)。免疫组化和免疫印迹实验结果显示, RAPA 治疗能明显下调肺组织中 TGF- β 1 和 α -SMA 的高表达 (图 5 和 6)。综上所述, RAPA 在治疗 PQ 中毒导致的肺纤维化中有重要价值。

关键词: 百草枯; 肺纤维化; 雷帕霉素; 甲强龙; 转化生长因子- β 1